食管切除术中常规放置空肠造瘘管的效果:系统评价与荟萃分析
该系统评价与荟萃分析检索至2020年12月的电子数据库,纳入12项研究共36284例患者,比较食管切除术联合或不联合术后喂养性空肠造瘘管。结果显示空肠造瘘管组30天全因死亡率风险比较无造瘘组为1.53(95%CI 1.37-1.70,P<.01;I²=0%,P=.80),手术时间无造瘘组更短(均差-37.18,95%CI -59.48至-14.87,P<.01),常见术后并发症两组无显著差异。作者认为食管切除术后喂养性空肠造瘘管可能降低30天全因死亡率,食管癌切除术中应考虑常规放置空肠造瘘管。
要点
- 空肠造瘘管组30天全因死亡率风险比较无造瘘组为1.53(95%CI 1.37-1.70,P<.01)。
- 手术时间无造瘘组更短(均差-37.18,95%CI -59.48至-14.87,P<.01)。
- 吻合口漏、住院时间、再入院、乳糜漏、脓毒症和肺炎两组无显著差异。
核心结论
- 食管切除术后喂养性空肠造瘘管可能降低30天全因死亡率,常见术后并发症无差异。
- 作者建议食管癌切除术中应考虑常规放置空肠造瘘管。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE和Cochrane中央对照试验注册库至2020年12月。
- 纳入12项研究(2项随机对照试验,10项观察性研究),共36284例参与者,比较食管切除术联合或不联合术后喂养性空肠造瘘管。
- 主要结局为30天死亡率,次要结局包括再入院率、住院时间、术后并发症(脓毒症、肺炎、乳糜漏和吻合口漏)及手术时间。
- 采用随机效应配对荟萃分析比较组间差异,使用纽卡斯尔-渥太华量表和Cochrane偏倚风险工具评估偏倚风险。
主要发现
- 空肠造瘘管组30天全因死亡率风险比较无造瘘组为1.53(95%CI 1.37-1.70,P<.01;I²=0%,P=.80)。
- 手术时间无造瘘组更短(均差-37.18;95%CI -59.48至-14.87;P<.01)。
- 吻合口漏发生率两组无显著差异(风险比0.88;95%CI 0.61-1.28;P=.50)。
- 住院时间(均差-0.22;95%CI -1.34至0.89;P=.69)和再入院(风险比0.97;95%CI 0.92-1.02;P=.20)两组无显著差异。
- 乳糜漏(风险比1.05;95%CI 0.34-3.27;P=.94)、脓毒症(风险比1.20;95%CI 0.96-1.50;P=.11)和肺炎(风险比0.88;95%CI 0.75-1.03;P=.11)两组无显著差异。
关键数值与推荐
- 30天全因死亡率:空肠造瘘管组较无造瘘组风险比为1.53(95%CI 1.37-1.70,P<.01;I²=0%,P=.80)。
- 手术时间:无造瘘组较空肠造瘘管组均差为-37.18(95%CI -59.48至-14.87,P<.01)。
- 吻合口漏:风险比0.88(95%CI 0.61-1.28,P=.50),两组无显著差异。
- 住院时间:均差-0.22(95%CI -1.34至0.89,P=.69),两组无显著差异。
- 再入院:风险比0.97(95%CI 0.92-1.02,P=.20),两组无显著差异。
临床怎么用
- 作者认为食管切除术后喂养性空肠造瘘管可能降低30天全因死亡率,常见术后并发症无差异。
- 作者建议食管癌切除术中应考虑常规放置空肠造瘘管。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Routine feeding jejunostomy tube post esophagectomy is being revaluated because of its associated postoperative complications. We performed a systematic review and meta-analysis to evaluate the effect of routine feeding jejunostomy tube insertion on mortality and postesophagectomy outcomes. METHODS: Electronic databases (MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials) were queried through December 2020. Included studies compared esophagectomy with and without postoperative feeding jejunostomy. The primary outcome was 30-day mortality. Secondary outcomes included readmission rate, length of stay, postoperative complications (sepsis, pneumonia, chyle leakage, and anastomotic leakage), and duration of surgery. Random effects pairwise meta-analysis was used to compare groups, and the risk of bias was assessed using the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool. RESULTS: The meta-analyses of 12 studies (2 randomized controlled trials, 10 observational) that enrolled 36,284 participants showed lower 30-day all-cause mortality in the jejunostomy tube group (risk ratio [RR] = 1.53 [95% CI, 1.37-1.70], P < .01; I2 = 0%, P = .80). Duration of surgery favored the no jejunostomy group (mean difference = -37.18; 95% CI, -59.48 to -14.87; P < .01). However, the 2 groups were not different in incidence of anastomotic leakage (RR = 0.88; 95% CI, 0.61-1.28; P = .50), length of stay (mean difference = -0.22; 95% CI, -1.34-0.89; P = .69), readmission (RR = 0.97; 95% CI, 0.92-1.02; P = .20), chyle leakage (RR = 1.05; 95% CI, 0.34-3.27; P = .94), sepsis (RR = 1.20; 95% CI, 0.96-1.50; P = .11), pneumonia (RR = 0.88; 95% CI, 0.75-1.03; P = .11). CONCLUSIONS: Feeding jejunostomy tube after esophagectomy might lead to lower 30-day all-cause mortality with no difference in common postesophagectomy complications. A routine insertion of a jejunostomy tube should be considered at the time of surgery for esophageal cancer resection.
引用
- Lee Y, Lu JY, Malhan R, et al. Effect of routine jejunostomy tube insertion in esophagectomy: A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2022. PMID: 35307215. doi:10.1016/j.jtcvs.2021.12.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。